MediWound
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, MediWound sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
MediWound: 7 sponsored US clinical trials, 2 recruiting.
MediWound sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 4 completed. 3 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Superficial Basal Cell Carcinoma, with 1 trials.
Upper-quartile sponsor footprint
MediWound sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
NCT06568627
A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma
NCT05157763
Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers
NCT06690177
A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers
NCT04817228
A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers
NCT03588130
A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns
NCT02148705
A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care
NCT02278718
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the MediWound pipeline
2 recruiting of 7 indexed (29% open); 4 completed (57%).
Phase mix: 3 late (III/IV) vs 4 early (I/II) (balanced across stages).
Top condition: Superficial Basal Cell Carcinoma (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
MediWound: open-pipeline peers nationwide
Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
MediWound sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
- Alnylam Pharmaceuticals · 29% recruiting · 49 trials
- Annovis Bio · 29% recruiting · 7 trials
Related
What to do with this MediWound page
7 registered trials is a research-attention snapshot, not an endorsement of MediWound or any single study.
- 2 of MediWound's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Superficial Basal Cell Carcinoma is the condition MediWound studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Superficial Basal Cell Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
MediWound pipeline card: 7 registered trials from official public datasets.Report a data error.